loading
Documents

Research.Publish.Connect.

Paper

Authors: Rini Noviyani ; P. A. Indrayathi ; I. N. G. Budiana ; Rasmaya Niruri ; K. Tunas and Tamara Candra Paramitha

Affiliation: Dhyana Pura University, Indonesia

ISBN: 978-989-758-349-0

Keyword(s): Chemotherapy, Paclitaxel-cisplatin, Ovarian Cancer, CA 125, BUN, Creatinine Serum

Abstract: The effectiveness and side effects of paclitaxel-cisplatin chemotherapy were assessed from the patient’s treatment progress and toxicity level. The objective was to evaluate these two criteria through the assessment of CA 125, BUN, and creatinine serum in patients as an approach to overcome the data limitation at Sanglah General Hospital. Observational retrospective research with patients who had epithelial ovarian cancer (EOC) at Stages I, II, III, and IV was conducted from February-March 2018. Patients’ blood samples were checked before the first and after the sixth cycle of chemotherapy. The data were processed with the Shapiro-Wilks normality test. As for the abnormally distributed data, they were analyzed statistically using the Wilcoxon test in SPSS. The mean values of CA 125 before the first and after the sixth chemotherapy cycles were 9,429.6 ± 1,5978.7 U/ml and 31.65 ± 36.07 U/ml, respectively (p-value= 0109). The mean values of BUN parameter were 10.63 ± 2.95 mg/dl and 14.83 ± 7.176 mg/dl (p-value= 0.315), respectively. The creatinine serums were averagely 0.693 ± 0.0929 mg/dl and 0.78 ± 0.2053 mg/dl (p-value= 0.417), respectively. There were differences in the levels of CA 125, BUN, and creatinine serum before the first and after the sixth cycles. (More)

PDF ImageFull Text

Download
CC BY-NC-ND 4.0

Sign In Guest: Register as new SciTePress user now for free.

Sign In SciTePress user: please login.

PDF ImageMy Papers

You are not signed in, therefore limits apply to your IP address 3.80.4.76

In the current month:
Recent papers: 100 available of 100 total
2+ years older papers: 200 available of 200 total

Paper citation in several formats:
Noviyani, R.; Indrayathi, P.; Budiana, I.; Niruri, R.; Tunas, K. and Paramitha, T. (2018). Evaluation of CA 125, BUN, and Creatinine Serum in Ovarian Cancer Patients Receiving Paclitaxel-Cisplatin Chemotherapy Treatment.In Proceedings of the 1st Muhammadiyah International Conference on Health and Pharmaceutical Development - Volume 1: MICH-PhD, ISBN 978-989-758-349-0, pages 33-38. DOI: 10.5220/0008238900330038

@conference{mich-phd18,
author={Rini Noviyani. and P. A. Indrayathi. and I. N. G. Budiana. and Rasmaya Niruri. and K. Tunas. and Tamara Candra Paramitha.},
title={Evaluation of CA 125, BUN, and Creatinine Serum in Ovarian Cancer Patients Receiving Paclitaxel-Cisplatin Chemotherapy Treatment},
booktitle={Proceedings of the 1st Muhammadiyah International Conference on Health and Pharmaceutical Development - Volume 1: MICH-PhD,},
year={2018},
pages={33-38},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0008238900330038},
isbn={978-989-758-349-0},
}

TY - CONF

JO - Proceedings of the 1st Muhammadiyah International Conference on Health and Pharmaceutical Development - Volume 1: MICH-PhD,
TI - Evaluation of CA 125, BUN, and Creatinine Serum in Ovarian Cancer Patients Receiving Paclitaxel-Cisplatin Chemotherapy Treatment
SN - 978-989-758-349-0
AU - Noviyani, R.
AU - Indrayathi, P.
AU - Budiana, I.
AU - Niruri, R.
AU - Tunas, K.
AU - Paramitha, T.
PY - 2018
SP - 33
EP - 38
DO - 10.5220/0008238900330038

Login or register to post comments.

Comments on this Paper: Be the first to review this paper.